Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Lung Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 107 articles: HTML format

Single Articles

January 2024
1. ZAHED H, Feng X, Sheikh M, Bray F, et al
   Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
   Int J Cancer. 2024;154:28-40.
   PubMed     Abstract available
   
   
   
2. KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al
   Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
   Int J Cancer. 2024;154:169-179.
   PubMed     Abstract available
   
   
   December 2023
3. MORISUE R, Kojima M, Suzuki T, Watanabe R, et al
   Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study.
   Int J Cancer. 2023;153:1997-2010.
   PubMed     Abstract available
   
   
   November 2023
4. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
   Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
   Int J Cancer. 2023;153:1784-1796.
   PubMed     Abstract available
   
   
   
5. PELOS G, Riester M, Pal J, Myacheva K, et al
   Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment.
   Int J Cancer. 2023 Nov 10. doi: 10.1002/ijc.34783.
   PubMed     Abstract available
   
   
   October 2023
6. WEI X, Sun D, Gao J, Zhang J, et al
   Development and evaluation of a polygenic risk score for lung cancer in never-smoking women: A large-scale prospective Chinese cohort study.
   Int J Cancer. 2023 Oct 17. doi: 10.1002/ijc.34765.
   PubMed     Abstract available
   
   
   
7. VAN VEELEN A, Veerman GDM, Verschueren MV, Gulikers JL, et al
   Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
   Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34742.
   PubMed     Abstract available
   
   
   
8. YU Z, Ni P, Yu H, Zuo T, et al
   Effectiveness of a single low-dose computed tomography screening for lung cancer: A population-based perspective cohort study in China.
   Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34741.
   PubMed     Abstract available
   
   
   
9. TOMONAGA Y, de Nijs K, Bucher HC, de Koning H, et al
   Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
   Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34746.
   PubMed     Abstract available
   
   
   September 2023
10. CHARVAT H, Fukui K, Matsuda T, Katanoda K, et al
    Impact of cancer and other causes of death on mortality of cancer patients: A study based on Japanese population-based registry data.
    Int J Cancer. 2023;153:1162-1171.
    PubMed     Abstract available
    
    
    
11. WANG F, Palmer N, Fox K, Liao KP, et al
    Large-scale real-world data analyses of cancer risks among patients with rheumatoid arthritis.
    Int J Cancer. 2023;153:1139-1150.
    PubMed     Abstract available
    
    
    
12. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    PubMed     Abstract available
    
    
    
13. KASTANA P, Ntenekou D, Mourkogianni E, Enake MK, et al
    Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth.
    Int J Cancer. 2023;153:1051-1066.
    PubMed     Abstract available
    
    
    August 2023
14. GUO T, Chen S, Wang Y, Zhang Y, et al
    Potential causal links of long-term air pollution with lung cancer incidence: From the perspectives of mortality and hospital admission in a large cohort study in southern China.
    Int J Cancer. 2023 Aug 23. doi: 10.1002/ijc.34699.
    PubMed     Abstract available
    
    
    
15. TREITSCHKE S, Weidele K, Varadarajan AR, Feliciello G, et al
    Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression.
    Int J Cancer. 2023 Aug 9. doi: 10.1002/ijc.34658.
    PubMed     Abstract available
    
    
    
16. REN S, Feng J, Ma S, Chen H, et al
    KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
    Int J Cancer. 2023;153:623-634.
    PubMed     Abstract available
    
    
    
17. DUGUE PA, Yu C, Hodge AM, Wong EM, et al
    Methylation scores for smoking, alcohol consumption and body mass index and risk of seven types of cancer.
    Int J Cancer. 2023;153:489-498.
    PubMed     Abstract available
    
    
    July 2023
18. CATELAN D, Biggeri A, Bucchi L, Manno V, et al
    Epidemiologic transition of lung cancer mortality in Italy by sex, province of residence and birth cohort (1920-1929 to 1960-1969).
    Int J Cancer. 2023 Jul 24. doi: 10.1002/ijc.34657.
    PubMed     Abstract available
    
    
    
19. WU SG, Gow CH, Chen YL, Liu YN, et al
    Different treatment efficacies and T790M acquisition of EGFR-TKIs on NSCLC patients with variable Del-19 subtypes of EGFR.
    Int J Cancer. 2023;153:352-363.
    PubMed     Abstract available
    
    
    
20. JI C, Lv J, Zhang J, Zhu M, et al
    Household air pollution and risk of incident lung cancer in urban China: A prospective cohort study.
    Int J Cancer. 2023 Jul 4. doi: 10.1002/ijc.34646.
    PubMed     Abstract available
    
    
    
21. STAAF J, Aine M, Nacer DF, Planck M, et al
    Molecular characteristics of lung adenocarcinoma with respect to patient age at diagnosis.
    Int J Cancer. 2023;153:197-209.
    PubMed     Abstract available
    
    
    June 2023
22. TSAKONAS G, Ekman S, Koulouris A, Adderley H, et al
    Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis.
    Int J Cancer. 2023 Jun 19. doi: 10.1002/ijc.34628.
    PubMed     Abstract available
    
    
    
23. CHENG C, Zhu G, Li Y, Wang H, et al
    Single-cell transcriptome analysis reveals cellular and molecular alterations in small cell lung cancer tumors following chemotherapy.
    Int J Cancer. 2023 Jun 19. doi: 10.1002/ijc.34629.
    PubMed     Abstract available
    
    
    
24. PANG LL, Liao J, Huang YH, Gan JD, et al
    Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.
    Int J Cancer. 2023;152:2338-2350.
    PubMed     Abstract available
    
    
    May 2023
25. DOU M, Li D, Zhu M, Guo W, et al
    Quantitative analysis of a novel DNA hypermethylation panel using bronchial specimen for lung cancer diagnosis.
    Int J Cancer. 2023 May 26. doi: 10.1002/ijc.34566.
    PubMed     Abstract available
    
    
    
26. WANG Y, Qiu W, Chen J, Meng W, et al
    ERbeta promoted invadopodia formation-mediated non-small cell lung cancer metastasis via the ICAM1/p-Src/p-Cortactin signaling pathway.
    Int J Cancer. 2023 May 22. doi: 10.1002/ijc.34563.
    PubMed     Abstract available
    
    
    
27. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
    Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
    Int J Cancer. 2023;152:2090-2098.
    PubMed     Abstract available
    
    
    April 2023
28. WANG P, Wang S, Sun Z, Li H, et al
    Systemic inflammation influences the prognosis of patients with radically resected non-small cell lung cancer and correlates with the immunosuppressive microenvironment.
    Int J Cancer. 2023 Apr 26. doi: 10.1002/ijc.34547.
    PubMed     Abstract available
    
    
    
29. YU L, Hu Y, Xu J, Qiao R, et al
    Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.
    Int J Cancer. 2023 Apr 20. doi: 10.1002/ijc.34536.
    PubMed     Abstract available
    
    
    
30. ZHANG Y, Liu W, Zhang H, Sun B, et al
    Extracellular vesicle long RNA markers of early-stage lung adenocarcinoma.
    Int J Cancer. 2023;152:1490-1500.
    PubMed     Abstract available
    
    
    
31. SUN C, Nagaoka K, Kobayashi Y, Maejima K, et al
    Immunotherapies targeting neoantigens are effective in PD-1 blockade-resistant tumors.
    Int J Cancer. 2023;152:1463-1475.
    PubMed     Abstract available
    
    
    
32. VAN GULIJK M, Belderbos B, Dumoulin D, Cornelissen R, et al
    Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma.
    Int J Cancer. 2023;152:1438-1443.
    PubMed     Abstract available
    
    
    March 2023
33. YANG W, Zhao X, Zheng A, Liu Z, et al
    Identification of MET fusions in solid tumors: A multicenter, large scale study in China.
    Int J Cancer. 2023;152:1259-1268.
    PubMed     Abstract available
    
    
    
34. CANNON-ALBRIGHT LA, Teerlink CC, Stevens J, Facelli JC, et al
    A rare FGF5 candidate variant (rs112475347) for predisposition to non-squamous, non-small-cell lung cancer.
    Int J Cancer. 2023 Mar 14. doi: 10.1002/ijc.34510.
    PubMed     Abstract available
    
    
    
35. CHENG ES, Velentzis LS, Weber M, Steinberg J, et al
    Female reproductive and hormonal factors and lung cancer mortality among never-smokers: a prospective cohort study of 287 408 Chinese women.
    Int J Cancer. 2023 Mar 14. doi: 10.1002/ijc.34508.
    PubMed     Abstract available
    
    
    February 2023
36. ALLIONE A, Viberti C, Cotellessa I, Catalano C, et al
    Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort.
    Int J Cancer. 2023;152:725-737.
    PubMed     Abstract available
    
    
    
37. DECHOW T, Riera-Knorrenschild J, Hackanson B, Janssen J, et al
    First-Line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study.
    Int J Cancer. 2023 Feb 9. doi: 10.1002/ijc.34467.
    PubMed     Abstract available
    
    
    December 2022
38. DWYER-NIELD LD, McArthur DG, Hudish TM, Hudish LI, et al
    PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model.
    Int J Cancer. 2022;151:2195-2205.
    PubMed     Abstract available
    
    
    
39. YU F, Peng M, Bai J, Zhu X, et al
    Comprehensive characterization of genomic and radiologic features reveals distinct driver patterns of RTK/RAS pathway in ground-glass opacity pulmonary nodules.
    Int J Cancer. 2022;151:2020-2030.
    PubMed     Abstract available
    
    
    November 2022
40. YU Y, Chen K, Fan Y
    Extensive-Stage Small-Cell Lung Cancer: Current Management and Future Directions.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34346.
    PubMed     Abstract available
    
    
    
41. NISHIYAMA H, Funamizu T, Iwata H, Endo H, et al
    Low apolipoprotein A1 was associated with increased risk of cancer mortality in patients following percutaneous coronary intervention: A 10-year follow-up study.
    Int J Cancer. 2022;151:1482-1490.
    PubMed     Abstract available
    
    
    
42. YANG LH, Lee RK, Kuo MH, Miao CC, et al
    Neuronal survival factor VGF promotes chemoresistance and predicts poor prognosis in lung cancers with neuroendocrine feature.
    Int J Cancer. 2022;151:1611-1625.
    PubMed     Abstract available
    
    
    October 2022
43. WU WY, Haider Z, Feng X, Heath AK, et al
    Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers - A retrospective nested case-control study in two prospective cohorts.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34340.
    PubMed     Abstract available
    
    
    
44. WEI Y, Xu B, He Q, Chen P, et al
    Serum total folate, 5-methyltetrahydrofolate and vitamin B12 concentrations on incident risk of lung cancer.
    Int J Cancer. 2022 Oct 2. doi: 10.1002/ijc.34307.
    PubMed     Abstract available
    
    
    September 2022
45. BEHRENS T, Ge C, Vermeulen R, Kendzia B, et al
    Occupational exposure to nickel and hexavalent chromium and the risk of lung cancer in a pooled analysis of case-control studies (SYNERGY).
    Int J Cancer. 2022 Sep 2. doi: 10.1002/ijc.34272.
    PubMed     Abstract available
    
    
    
46. YANG Z, Tian H, Li L, Li C, et al
    PSC subtyping based on TTF-1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies.
    Int J Cancer. 2022;151:717-729.
    PubMed     Abstract available
    
    
    
47. YUI Y, Kumai J, Watanabe K, Wakamatsu T, et al
    Lung fibrosis is a novel therapeutic target to suppress lung metastasis of osteosarcoma.
    Int J Cancer. 2022;151:739-751.
    PubMed     Abstract available
    
    
    August 2022
48. RAJAN A, Gray JE, Devarakonda S, Birhiray R, et al
    Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-Squamous Non-Small Cell Lung Cancer.
    Int J Cancer. 2022 Aug 27. doi: 10.1002/ijc.34267.
    PubMed     Abstract available
    
    
    
49. AKHOUNDOVA D, Hussung S, Sivakumar S, Topfer A, et al
    ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
    Int J Cancer. 2022 Aug 22. doi: 10.1002/ijc.34257.
    PubMed     Abstract available
    
    
    
50. MUI CW, Chan WN, Chen B, Cheung AH, et al
    Targeting YAP1/TAZ in non-small-cell lung carcinoma: from molecular mechanisms to precision medicine.
    Int J Cancer. 2022 Aug 19. doi: 10.1002/ijc.34249.
    PubMed     Abstract available
    
    
    
51. GAO G, Cui L, Zhou F, Jiang T, et al
    Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
    Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34239.
    PubMed     Abstract available
    
    
    
52. RASHIDIAN H, Hadji M, Gholipour M, Naghibzadeh-Tahami A, et al
    Opium use and risk of lung cancer: A multicenter case-control study in Iran.
    Int J Cancer. 2022 Aug 13. doi: 10.1002/ijc.34244.
    PubMed     Abstract available
    
    
    
53. MARTINI G, Ciardiello D, Dallio M, Famiglietti V, et al
    Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Int J Cancer. 2022;151:473-480.
    PubMed     Abstract available
    
    
    
54. BUERGY D, Wurschmidt F, Gkika E, Horner-Rieber J, et al
    Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.
    Int J Cancer. 2022;151:412-421.
    PubMed     Abstract available
    
    
    July 2022
55. HEATH AK, Muller DC, van den Brandt PA, Critselis E, et al
    Diet-wide association study of 92 foods and nutrients and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study.
    Int J Cancer. 2022 Jul 13. doi: 10.1002/ijc.34211.
    PubMed     Abstract available
    
    
    
56. KORHONEN T, Hjelmborg J, Harris JR, Clemmensen S, et al
    Cancer in twin pairs discordant for smoking: The Nordic Twin Study of Cancer.
    Int J Cancer. 2022;151:33-43.
    PubMed     Abstract available
    
    
    June 2022
57. YARMOLINSKY J, Amos CI, Hung RJ, Moreno V, et al
    Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk.
    Int J Cancer. 2022 Jun 23. doi: 10.1002/ijc.34180.
    PubMed     Abstract available
    
    
    
58. BISCHOFF P, Trinks A, Wiederspahn J, Obermayer B, et al
    The single-cell transcriptional landscape of lung carcinoid tumors.
    Int J Cancer. 2022;150:2058-2071.
    PubMed     Abstract available
    
    
    
59. ZAORSKY NG, Wang X, Lehrer EJ, Tchelebi LT, et al
    Retrospective comparative effectiveness research: Will changing the analytical methods change the results?
    Int J Cancer. 2022;150:1933-1940.
    PubMed     Abstract available
    
    
    
60. MOONEN L, Mangiante L, Leunissen DJG, Lap LMV, et al
    Differential Orthopedia Homeobox expression in pulmonary carcinoids is associated with changes in DNA methylation.
    Int J Cancer. 2022;150:1987-1997.
    PubMed     Abstract available
    
    
    
61. LI M, Zhang L, Charvat H, Callister ME, et al
    The influence of postscreening follow-up time and participant characteristics on estimates of overdiagnosis from lung cancer screening trials.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34167.
    PubMed     Abstract available
    
    
    
62. MAILLE E, Levallet J, Dubois F, Antoine M, et al
    A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT-0701 MAPS phase 3 trial.
    Int J Cancer. 2022;150:1889-1904.
    PubMed     Abstract available
    
    
    May 2022
63. WONG KY, Cheung AH, Chen B, Chan WN, et al
    Cancer-associated fibroblasts in non-small cell lung cancer: from molecular mechanisms to clinical implications.
    Int J Cancer. 2022 May 23. doi: 10.1002/ijc.34127.
    PubMed     Abstract available
    
    
    
64. SU C, Zhou J, Qiang H, Zhao J, et al
    Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China.
    Int J Cancer. 2022 May 17. doi: 10.1002/ijc.34123.
    PubMed     Abstract available
    
    
    April 2022
65. GUO LW, Meng QC, Zheng LY, Chen Q, et al
    Special issue "The advance of solid tumor research in China": Participants with a family history of cancer have a higher participation rate in low-dose computed tomography for lung cancer screening.
    Int J Cancer. 2022 Apr 1. doi: 10.1002/ijc.34010.
    PubMed     Abstract available
    
    
    March 2022
66. ZHAO Y, Gao YT, Zhang X, Rockwood AL, et al
    Endogenous sex hormones, aromatase activity and lung cancer risk in postmenopausal never-smoking women.
    Int J Cancer. 2022 Mar 26. doi: 10.1002/ijc.34005.
    PubMed     Abstract available
    
    
    
67. ABRAHAM G, Noronha V, Rajappa S, Agarwal A, et al
    The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India.
    Int J Cancer. 2022;150:1045-1052.
    PubMed     Abstract available
    
    
    
68. HERMANS BCM, Derks JL, Hillen LM, van der Baan I, et al
    In-depth molecular analysis of combined and co-primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma.
    Int J Cancer. 2022;150:802-815.
    PubMed     Abstract available
    
    
    February 2022
69. NGUYEN PT, Katanoda K, Saito E, Hori M, et al
    Trends in lung cancer incidence by gender, histological type and stage at diagnosis in Japan, 1993-2015: A multiple imputation approach.
    Int J Cancer. 2022 Feb 9. doi: 10.1002/ijc.33962.
    PubMed     Abstract available
    
    
    December 2021
70. ZHAO Y, Li S, Yang X, Chu L, et al
    Overall survival benefit of Osimertinib and clinical value of upfront cranial local therapy in untreated EGFR-mutant non-small cell lung cancer with brain metastasis.
    Int J Cancer. 2021 Dec 16. doi: 10.1002/ijc.33904.
    PubMed     Abstract available
    
    
    
71. BAEK YH, Kang EJ, Hong S, Park SH, et al
    Survival outcomes of patients with non-small cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Int J Cancer. 2021 Dec 7. doi: 10.1002/ijc.33892.
    PubMed     Abstract available
    
    
    October 2021
72. BOOSMAN RJ, Dorlo TPC, de Rouw N, Burgers JA, et al
    Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
    Int J Cancer. 2021;149:1576-1584.
    PubMed     Abstract available
    
    
    
73. MIURA A, Yamada D, Nakamura M, Tomida S, et al
    Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.
    Int J Cancer. 2021;149:1593-1604.
    PubMed     Abstract available
    
    
    September 2021
74. HUANG Y, Soon YY, Aminkeng F, Tay SH, et al
    Risk factors for Immune-related Adverse Events from anti-PD-1 or anti PD-L1 treatment in an Asian cohort of non-small cell lung cancer patients.
    Int J Cancer. 2021 Sep 25. doi: 10.1002/ijc.33822.
    PubMed     Abstract available
    
    
    
75. HUANG CH, Ju JS, Chiu TH, Huang AC, et al
    Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation.
    Int J Cancer. 2021 Sep 24. doi: 10.1002/ijc.33821.
    PubMed     Abstract available
    
    
    
76. ROGAVA M, Braun AD, van der Sluis TC, Shridhar N, et al
    Tumor cell intrinsic TLR4 signaling promotes melanoma progression and metastatic dissemination.
    Int J Cancer. 2021 Sep 16. doi: 10.1002/ijc.33804.
    PubMed     Abstract available
    
    
    August 2021
77. JI M, Du L, Ma Z, Xie J, et al
    Circulating C-reactive protein increases lung cancer risk: results from a prospective cohort of UK Biobank.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33780.
    PubMed     Abstract available
    
    
    
78. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available
    
    
    
79. RISSANEN E, Heikkinen S, Seppa K, Ryynanen H, et al
    Incidence trends and risk factors of lung cancer in never smokers - Pooled analyses of seven cohorts.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33765.
    PubMed     Abstract available
    
    
    
80. TANIGUCHI H, Natori Y, Miyagi Y, Hayashi K, et al
    Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.
    Int J Cancer. 2021;149:646-656.
    PubMed     Abstract available
    
    
    July 2021
81. ROSIGKEIT S, Kruchem M, Thies D, Kreft A, et al
    Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer.
    Int J Cancer. 2021 Jul 31. doi: 10.1002/ijc.33756.
    PubMed     Abstract available
    
    
    
82. BUERGY D, Wurschmidt F, Gkika E, Horner-Rieber J, et al
    Stereotactic or conformal radiotherapy for adrenal metastases: Patient characteristics and outcomes in a multicenter analysis.
    Int J Cancer. 2021;149:358-370.
    PubMed     Abstract available
    
    
    June 2021
83. DOMINE GOMEZ M, Csoszi T, Jaal J, Kudaba I, et al
    Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
    Int J Cancer. 2021 Jun 10. doi: 10.1002/ijc.33705.
    PubMed     Abstract available
    
    
    May 2021
84. MU R, Liu H, Luo S, Patz EF Jr, et al
    Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival.
    Int J Cancer. 2021 May 31. doi: 10.1002/ijc.33702.
    PubMed     Abstract available
    
    
    
85. YU X, Sheng J, Pan G, Fan Y, et al
    Real-World Utilization of EGFR TKIs and Prognostic Factors for Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases.
    Int J Cancer. 2021 May 10. doi: 10.1002/ijc.33677.
    PubMed     Abstract available
    
    
    
86. XIA Y, Ying S, Jin R, Wu H, et al
    Application of a classifier combining bronchial transcriptomics and chest CT features facilitates the diagnostic evaluation of lung cancer in smokers and non-smokers.
    Int J Cancer. 2021 May 8. doi: 10.1002/ijc.33675.
    PubMed     Abstract available
    
    
    
87. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available
    
    
    
88. MORGAN E, Arnold M, Rutherford M, Bardot A, et al
    The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project).
    Int J Cancer. 2021 May 1. doi: 10.1002/ijc.33620.
    PubMed     Abstract available
    
    
    April 2021
89. HENNESSY M, Wahba A, Felix K, Cabrera M, et al
    Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
    Int J Cancer. 2021;148:1928-1937.
    PubMed     Abstract available
    
    
    
90. CAI L, Chen Y, Tong X, Wu X, et al
    The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.
    Int J Cancer. 2021 Apr 2. doi: 10.1002/ijc.33583.
    PubMed     Abstract available
    
    
    
91. HUANG RSP, Haberberger J, Sokol E, Schrock AB, et al
    Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Int J Cancer. 2021;148:1778-1788.
    PubMed     Abstract available
    
    
    
92. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available
    
    
    March 2021
93. LAUTZ TB, Farooqui Z, Jenkins T, Heaton TE, et al
    Thoracoscopy vs thoracotomy for the management of metastatic osteosarcoma: A Pediatric Surgical Oncology Research Collaborative Study.
    Int J Cancer. 2021;148:1164-1171.
    PubMed     Abstract available
    
    
    February 2021
94. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available
    
    
    January 2021
95. LILJEDAHL H, Karlsson A, Oskarsdottir GN, Salomonsson A, et al
    A gene expression-based single sample predictor of lung adenocarcinoma molecular subtype and prognosis.
    Int J Cancer. 2021;148:238-251.
    PubMed     Abstract available
    
    
    November 2020
96. MCGUIRE JJ, Nerlakanti N, Lo CH, Tauro M, et al
    Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
    Int J Cancer. 2020;147:2811-2823.
    PubMed     Abstract available
    
    
    
97. HAAKENSEN VD, Khadse A, Sandhu V, Halvorsen AR, et al
    Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy.
    Int J Cancer. 2020;147:2957-2966.
    PubMed     Abstract available
    
    
    
98. MA J, Klemm J, Gerardo-Ramirez M, Frappart L, et al
    Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin.
    Int J Cancer. 2020;147:2564-2577.
    PubMed     Abstract available
    
    
    
99. CHENG C, Zhao Y, Schaafsma E, Weng YL, et al
    An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.
    Int J Cancer. 2020;147:2621-2633.
    PubMed     Abstract available
    
    
    October 2020
100. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
     Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
     Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
     PubMed     Abstract available
     
     
     September 2020
101. SIRRI E, Kieschke J, Vohmann C, Katalinic A, et al
     Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: A population-based study.
     Int J Cancer. 2020;147:1548-1558.
     PubMed     Abstract available
     
     
     
102. ENGLINGER B, Laemmerer A, Moser P, Kallus S, et al
     Lipid droplet-mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib.
     Int J Cancer. 2020;147:1680-1693.
     PubMed     Abstract available
     
     
     August 2020
103. GRAU N, Scherer SD, Rothley M, Rosswag S, et al
     Spatiotemporally controlled induction of gene expression in vivo allows tracking the fate of tumor cells that traffic through the lymphatics.
     Int J Cancer. 2020;147:1190-1198.
     PubMed     Abstract available
     
     
     
104. MENGONI M, Braun AD, Gaffal E, Tuting T, et al
     The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells.
     Int J Cancer. 2020 Aug 13. doi: 10.1002/ijc.33252.
     PubMed     Abstract available
     
     
     May 2020
105. ZONNEVILLE J, Colligan S, Grant S, Miller A, et al
     Blockade of p38 kinase impedes the mobilization of protumorigenic myeloid populations to impact breast cancer metastasis.
     Int J Cancer. 2020 May 25. doi: 10.1002/ijc.33050.
     PubMed     Abstract available
     
     
     
106. HE Q, Li X, He L, Li Y, et al
     Pericyte dysfunction due to Shb gene deficiency increases B16F10 melanoma lung metastasis.
     Int J Cancer. 2020 May 22. doi: 10.1002/ijc.33110.
     PubMed     Abstract available
     
     
     March 2020
107. KATO M, Onoyama I, Yoshida S, Cui L, et al
     Dual specificity phosphatase 6 plays a critical role in the maintenance of a cancer stem-like cell phenotype in human endometrial cancer.
     Int J Cancer. 2020 Mar 11. doi: 10.1002/ijc.32965.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.